Log in to your Inderes Free account to see all free content on this page.
Genmab
1,361.5
DKK
+0.41 %
Less than 1K followers
GMAB
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Investor consensus
+0.41%
-15.85%
-8.78%
-8.32%
-14.77%
-35.96%
-42.65%
-0.07%
+3,892.67%
Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read moreMarket cap
90.13B DKK
Turnover
53.21M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
8.5.
2025
Interim report Q1'25
7.8.
2025
Interim report Q2'25
6.11.
2025
Interim report Q3'25
All
Press releases
ShowingAll content types
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio